Oct 2026· Physiological Reports· Vol 14· 0 citations· 46 references
Medicine
TL;DR
It is observed that activation of Toll‐like receptor‐4 (TLR4) using the selective agonist CRX572 induced three distinct functional effects in cultured podocytes, which may alter glomerular function via parallel pleiotropic signaling cascades in podocytes.
Abstract
Proteinuria is a cardinal symptom of kidney disease, but common transient proteinurias may reflect a normal physiological response to distant tissue damage or infection. Here we observed that activation of Toll‐like receptor‐4 (TLR4) using the selective agonist CRX572 induced three distinct functional effects in cultured podocytes. TLR4 activation evoked a reversible increase in albumin flux (PAlb) across a confluent layer of podocytes in 60 m or less. At 24 h matrix metalloproteinase‐dependent shedding of nephrin ectodomains was detected. Finally, apoptosis occurred after 72 h. These effects were blocked by TAK242, a selective TLR4 antagonist. TLR4 activation engaged multiple intracellular transduction cascades. Activation of Erk was observed at 30 m, increased reactive oxygen species (ROS) was seen at 60 m and 24 h, and activation of NFκB was seen with 24 h of TLR activation. The increase in PAlb required increased ROS and activation of Erk. The subsequent nephrin ectodomain shedding also required Erk signaling but did not require increased cytosolic ROS or NFκB activation. Finally, TLR4‐evoked apoptosis required both increased ROS and activation of NFκB but did not require Erk activation. Innate immune signaling through TLR4 may alter glomerular function via parallel pleiotropic signaling cascades in podocytes.
Summary The mechanisms underlying focal segmental glomerulosclerosis (FSGS), particularly podocyte damage, remain unclear. We found that patients with FSGS have significantly elevated serum and urine levels of SH3YL1, especially in more severe cases. Adriamycin stimulates SH3YL1 secretion, which induces proinflammatory...
Hye Eun Lee, J. Ghee, Eun Jung An et al.· iScience· 0 citations
The TLR4 pathway may be involved in immediate cell survival mechanisms after injury, as massive necrosis and elevated serum creatinine were observed following early inhibition of the TLR4 pathway, whereas late inhibition preserved tissue architecture and function.
Yamna Haider· Pakistan Journal of Pharmace...· 0 citations
HMGN5 is identified as a novel regulator of IFNAR2-related pyroptosis-associated signaling in renal tubular epithelial cells and it is suggested that the HMGN5-IFNAR2 axis represents a pathophysiological pathway of interest in CKD that warrants further investigation.
Xue Rong, Jing Xu, Jie-Nan Zhang et al.· International Journal of Mol...· 0 citations
It is demonstrated that uPA-activated uPAR engages TLR4-associated signaling to intensify macrophage-driven inflammation, oxidative stress, and fibrotic remodeling, redefine uPAR as a molecular switch governing maladaptive kidney repair and identify the uPA/uPAR-TLR4 signaling interface as a promising therapeutic targe...
Sheng-Chun Zheng, Yan Chen, Jiao-Na Liu et al.· Antioxidants and Redox Signa...· 0 citations
BACKGROUND
Diabetic kidney disease (DKD) involves persistent tubular inflammation. Tetrandrine (Tet), a bioactive alkaloid from Stephania tetrandra S. Moore, has renoprotective potential, but its effects on TLR4-associated inflammatory signaling remain incompletely understood.
METHODS
Male KK-Ay mice received Tet (10...
Yan Yan, Wen-Ru Wang, Heng Chen et al.· International Immunopharmaco...· 0 citations
Renal ischemia–reperfusion injury (IRI), characterized by enhanced inflammation, is a leading cause of acute kidney injury (AKI) with limited treatments beyond supportive dialysis. Biglycan through toll-like receptors (TLR)2/TLR4 signaling aggravates tissue damage in acute renal IRI. This study aimed to identify the TL...
Rosetta Merline, L. T. Hsieh, Jinyang Zeng-Brouwers et al.· Cellular & Molecular Biology...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.